Despite promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from PBMs. The organizations are often creating barriers to coverage, such as steep price requirements and PA that restrict consumer opportunity. Market indicate that the access hurdles